Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand. In contrast, shares of competitor Hims & Hers Health (HIMS) are plummeting following this news.

Market Domination hosts Madison Mills and Josh Schafer discuss the news and Citi's take on it.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Angel Smith